# Characterizing Declines in US Overdose Deaths Compared to Exponential Predictions

Joseph R. Friedman, MD, PhD, MPH[1*], Joseph J. Palamar, PhD[2], Daniel Ciccarone, MD[3], Tommi L. Gaines, DrPH[4], Annick Borquez, PhD[4], Chelsea L. Shover, PhD[5], Steffanie A. Strathdee, PhD[4]

[1]Department of Psychiatry, University of California, San Diego, San Diego, CA
[2]Department of Population Health, NYU Grossman School of Medicine, New York, NY
[3]Department of Family Community Medicine, University of California, San Francisco, San Francisco, CA
[4]Department of Medicine, University of California, San Diego, San Diego, San Diego, CA
[5]Department of Medicine, University of California Los Angeles, Los Angeles, CA

*Correspondence to:
Joseph Friedman, MD PhD, MPH, University of California, San Diego, 200 W Arbor Dr, San Diego, CA, 92103. jofriedman@health.ucsd.edu

**Word Count:** 2,997/3,000 words

## Key Points

### Question

To what extent are recent decreases in US overdose mortality deviating from prior exponential growth, and how have substance-specific, racial/ethnic, and geographic trends shifted?

### Findings

Decreases in overdose deaths between June 2023 and December 2024 represent the first significant large magnitude drop below the exponential growth curve, driven by falling illicit fentanyl mortality. However, deaths involving stimulants and xylazine continue to rise. The Western US shifted from the least-affected region to the most affected by overdose mortality. Racial gaps remain large but shrunk by a modest margin.

### Meaning

The course of the US overdose crisis is no longer consistent with an exponential growth curve, but novel substances and adulterants represent a potential driver of increased deaths in the future. Shifts occurring in 2024 were disproportionate by geography and race/ethnicity.

## Abstract

**Importance**

After decades of growth described nearly perfectly with an exponential curve, US overdose mortality has begun to decrease.

**Objective**

To determine whether decreases in overdose mortality between 2023 and 2024 deviate from a previously defined exponential growth curve, and assess how they differ by substance involvement, geography, race/ethnicity, demographic, and other key dimensions.

**Design, Setting, and Participants**

Observational study examining overdose deaths in the US between January 1980-December 2024. Mortality trends were compared to an exponential growth curve, fit on data from 1980 to 2016.

**Exposures**

Year and month of occurrence of overdose death; substance involvement; census region and division; state; county; race/ethnicity, age, and sex.

**Main Outcome and Measures**

Annual or monthly (annualized) overdose deaths per 100,000 population.

**Results**

After precipitously surpassing exponential growth predictions in 2020-2023, overdose deaths fell sharply from approximately 32 per 100,000 in 2021-2023 to 23.7 in 2024, below the lower bound of the exponential curve prediction (24.98) for the first time since 2001. Monthly data show consistent decreases between June 2023 and December 2024. Decreases reflected

declining illicit fentanyl-involved deaths (with and without stimulants); however, deaths involving stimulants without fentanyl, and those involving xylazine, continued to increase in 2024. Death rates in the Northeast, South and Midwest fell to 19.5, 19.4 and 17.3 per 100,000, respectively, in December 2024, but remained elevated in the West at 27.2 per 100,000. Non-Hispanic Black and African Americans had the largest decrease in death rates in 2023-2024 falling 29.3%, but remained elevated at 36.0 per 100,000, compared to the national average of 23.7 per 100,000. Non-Hispanic American Indian and Alaska Native individuals had the highest overdose mortality rate in 2024, at 50.8 per 100,000.

**Conclusions and Relevance**

Recent decreases in overdose deaths are encouraging, unprecedented, and represent the first significant, large-magnitude deviation below exponential growth. However, policymakers, clinicians, and public health officials should be prepared for the possibility that a resurgence could occur, especially if novel synthetic drugs change the risk environment of illicit drug use. Stimulants and xylazine continue to represent increasingly important public health challenges. Racial gaps remained large but shrunk by a modest margin.

## Introduction

Overdose death rates in the US have begun decreasing, drawing considerable public attention.[1] Earlier data described these trends at the national level,[2] with an overall downtrend beginning mid-year 2023.[3] However, more updated and detailed information is needed to inform prevention efforts, including a) how significantly these decreases in overdose mortality deviate from previous exponential growth trends, and b) how they differ by substance involvement, geography, race/ethnicity, and demographic categories.

Overdose deaths in the US have been characterized with a 'four wave' paradigm, wherein an escalating overdose crisis was attributed to shifting drug profiles over time.[4–6] The first wave was characterized by widespread access to prescription opioids—directly or indirectly through the healthcare system—leading to a surge in deaths involving commonly prescribed opioids.[7] As opioid deprescription limited access, in wave two, heroin filled the void left in the illicit opioid market, and heroin-involved deaths predominated.[8] Wave three involved the market takeover of illicitly-manufactured synthetic opioids, primarily fentanyls, whereby fentanyl-involved deaths came to represent the largest share of overdose mortality.[8] As fentanyl induced shifts in the illicit market and drug consumption behaviors, it ushered in the fourth wave, characterized by a rise in polysubstance overdose deaths, especially involving the combination of fentanyl with illicit stimulants such as cocaine and methamphetamine.[4,5] Deaths involving the combination of fentanyl with the veterinary sedative xylazine also increased during this period.[9,10]

These four waves of the overdose crisis have seen epidemiological differences by geography and race/ethnicity. Overdose death rates have historically been lower in the Western US, although the region has started to 'catch up' as illicit fentanyl arrived to the West.[11] The third and fourth waves of the overdose crisis have also driven sharp racial and ethnic inequalities in overdose, with Black and African Americans, as well as American Indian and Alaska Natives disproportionately affected.[12] One study found that mortality decreased among Non-Hispanic White individuals, but as of 2023, were still increasing among the most affected racial/ethnic minority groups, suggesting widening disparities despite overall gains at the population level.[3] More recent evidence is needed to evaluate if racial/ethnic minority communities are now experiencing similar decreases in overdose trends.

More insight is also needed to contextualize what recent decreases may mean for the long-term course of the overdose crisis in the US. As Jalal et al. noted in 2018, US overdose mortality between 1980 and 2016 followed a nearly mathematically perfect exponential growth curve.[6] Although overdose death rates have generally followed this pattern for the past four decades, previous smaller-magnitude exceptions have been described. For instance, after growth surpassed exponential predictions during 2016-2017—likely due, in part, to a transient spike in carfentanil-related deaths—decreases occurred in 2018, representing a return to the exponential growth curve.[13] It remains to be determined whether high magnitude increases in overdose mortality occurring during the COVID-19 pandemic,[14] and more recent decreases,[3] remain consistent with an overall exponential growth curve or if new patterns are emerging.

113 Here, we leverage recent records to describe overdose trends between January 1980-December
114 2024. We evaluate whether mortality rates remained consistent with an overall exponential
115 growth curve, and assess trends by substance-involvement, race/ethnicity, geography and
116 demographics.
117
118 **Methods**
119 Nationally representative drug overdose death data from the National Vital Statistics System
120 (NVSS) were obtained describing the 1980-2024 period. Drug overdose deaths were defined by
121 ICD-10 underlying cause of death codes X40–X44 (unintentional), X60–X64 (suicide), X85
122 (homicide), and Y10–Y14 (undetermined intent).[15] Recorded deaths from 2024 were provisional
123 and may slightly underestimate finalized records, whereas records from 2023 and prior were
124 finalized. Data on deaths between 1999 and 2024 were obtained for overdose-related deaths
125 overall and stratified by year, month, race/ethnicity, geography, and substance-involvement via
126 the Centers for Disease Control and Prevention (CDC) Wide-ranging ONline Data for
127 Epidemiologic Research (WONDER) platform.[15] As the CDC WONDER platform does not provide
128 records before 1999, mortality rates at the national level between 1980 and 1998 were
129 obtained from a separate publication using NVSS data.[16]
130
131 Substance involvement was characterized using ICD-10 multiple cause of death codes including
132 prescription opioids (T40.2), heroin (T40.1), synthetic opioids (primarily and herein referred to
133 as fentanyl) (T40.4),[5] cocaine (T40.5), psychostimulants with abuse potential (primarily and
134 herein referred to as methamphetamine) (T43.6),[17] and xylazine (T42.7 or T46.5).[9] Of note,

T40.4 and T43.6 represent umbrella codes for 'Other Synthetic Narcotics' and 'Psychostimulants with Abuse Potential' respectively, which are widely used in epidemiological research to represent illicit fentanyl and methamphetamine, respectively, as they mostly code for these substances.[9,17,18] For simplicity, we use the terms 'fentanyl' and 'methamphetamine' throughout the text. Nevertheless, a small number of other substances (such as nitazenes or U-compounds, in the case of T40.4) are also represented by these codes.

To recreate the exponential curve defined by Jalal et al., we fit a bivariate linear regression model with the outcome as the natural log of deaths per 100,000 population and the explanatory variable of year of occurrence, using national overdose death data from 1980 to 2016.[6] The model was linearly extrapolated to make predictions for 2017-2024. Observed trends between 1980 and 2024 were compared to model predictions, with 95% confidence intervals, drawn from the fitted model assuming a normal distribution. All analyses were conducted in R version 4.4.1.

**Results**

Figure 1 provides a simplified schema representing the four waves of the US overdose crisis. Wave one reflects deaths due to prescription opioids (with fentanyl co-involvement omitted), wave two is shown by deaths involving heroin (with fentanyl co-involvement omitted). Waves three and four correspond to fentanyl-involved deaths without and with stimulant co-involvement, respectively. Xylazine-involved deaths, and deaths involving stimulants without fentanyl co-involvement are also shown as key drug mortality trends that are not decreasing.

157 During the COVID-19 pandemic in 2020, overdose mortality per 100,000 population rose sharply
158 above the exponential growth curve defined by Jalal et al (Figure 2A). Rates remained elevated
159 above the curve prediction, albeit relatively flat at about 32 deaths per 100,000 population,
160 between 2021 and 2023. In 2024, national overdose mortality fell precipitously to 23.7 per
161 100,000, dropping below the lower bound of the exponential curve prediction (which was 24.98
162 per 100,000) for the first time since 2001 (and for the first time ever to a large-magnitude
163 degree). Month-to-month trends highlight that mortality began to fall in June 2023 and
164 decreased steadily through December 2024 (Figure 3).
165
166 Overdose mortality has been characterized by a shifting profile of related drugs over time
167 (Figure 2B). The contributions of prescription opioids, heroin, and fentanyl without, and with
168 stimulants (roughly corresponding to waves 1-4 of the overdose crisis, respectively)[5] are
169 declining in the latest data. Mortality rates for overdose deaths involving prescription opioids
170 and heroin (with fentanyl co-involved deaths omitted) reached inflection points and began to
171 fall in 2016 and 2015, respectively, marking the decline of waves one and two of the crisis.
172 Overdose mortality rates involving illicit fentanyl without stimulant co-involvement began to fall
173 in 2022, marking the decline of wave three of the overdose crisis. Overdose death rates
174 involving fentanyl with stimulants declined for the first time in 2024, beginning the decline of
175 wave four. Deaths involving methamphetamine (without fentanyl co-involvement) and cocaine
176 (without fentanyl co-involvement) continued increasing between 2023 and 2024, consistent
177 with an overall trend of increasing stimulant-related deaths. Deaths involving xylazine also
178 represented an increasing proportion of fentanyl-involved deaths between 2023 and 2024,

179 rising from being co-involved in 8.3% of fentanyl-involved overdose deaths in 2023 to 12.6% of
180 fentanyl-involved deaths in 2024.
181
182 The overall decrease in overdose deaths in the US in 2023-2024 has been largely driven by
183 declines in deaths involving illicit fentanyl (Figure 4). Fentanyl-involved deaths without and with
184 stimulants dropped from 31,193 and 41,583 in 2023 respectively to 19,673 and 28,062
185 respectively in 2024. In contrast, the number of deaths involving stimulants, without fentanyl,
186 grew from 18,142 in 2023 to 18,907 in 2024, representing 17.3% of all overdose deaths in 2023,
187 and 23.8% of overdose deaths in 2024 (Figure 4).
188
189 Overdose mortality decreased differentially by region (Figure 3; Figure 5). In 2018, the
190 Northeast had the highest overdose death rates, followed by the South and Midwest, with the
191 West considerably lower (Figure 3). In 2024, overdose mortality in the West surpassed that of
192 other regions. Death rates in the Northeast, South and Midwest fell to 19.5, 19.4 and 17.3 per
193 100,000 respectively in December 2024, whereas in the West they remained more elevated, at
194 27.2 per 100,000 in December 2024. Between 2023 and 2024 death rates fell by 28.7% in the
195 Northeast, 28.2% in the Midwest, and 26.5% in the South, compared to 14.7% in the West.
196
197 Among Census divisions, the largest decreases between 2023 and 2024 were observed in East
198 North Central (which includes Illinois, Indiana, Michigan, Ohio, and Wisconsin) with a 30.5%
199 decline, and the South Atlantic (Delaware, Florida, Georgia, Maryland, North Carolina, South
200 Carolina, Virginia, West Virginia, and Washington, D.C.) with a decline of 29.2%. The smallest

decreases were observed in the Mountain Division (including Arizona, Colorado, Idaho, Montana, Nevada, New Mexico, Utah, and Wyoming) with 9.7% and the Pacific (Alaska, Hawaii, California, Oregon, and Washington) with 17.2%. Among states, the largest decreases during this period were observed in West Virginia (40.4% decrease), Virginia (29.7% decrease) and Delaware (32.7% decrease). Hawaii and South Dakota were the only states to register an increase in overdose mortality between 2023 and 2024. (4.0% and 3.1% increases, respectively), and Utah and Nevada experienced modest decreases (2.7% and 3.5% respectively; Figure 6). In 2024, the highest overall overdose death rates were in Washington, D.C. (46.4 per 100,000) and West Virginia (46.4 per 100,000) whereas Nebraska (7.8 per 100,000), South Dakota (10.7 per 100,000), and Iowa (13.3 per 100,000) had the lowest rates. Among the ten counties with the largest numbers of deaths in 2024, Wayne County, Michigan (home to Detroit) and Cook County, Illinois (home to Chicago) had the largest relative decreases (41.6% and 30.3%, respectively). Clark County, Nevada (home to Las Vegas) saw a small increase in deaths (3.0%) and Maricopa County, Arizona (home to Phoenix) experienced the smallest decrease of 3.6%.

Decreases in overdose mortality also varied by race/ethnicity and other demographic factors (Figure 5). Non-Hispanic Black and African Americans had the largest decrease in overdose death rates between 2023 and 2024 of any group assessed, falling 29.3%. Nevertheless, this group had an overdose death rate in 2024 of 36.0 per 100,000, substantially higher than the national average of 23.7. Non-Hispanic American Indian and Alaska Native individuals had the highest overdose mortality rate of any group assessed in 2024, at 50.8, and experienced below-average decreases between 2023 and 2024, of 20.1%. Non-Hispanic White individuals had

223 below-average overdose death rates in 2024 of 24.8 and saw declines similar to the national
224 average.
225
226 Relative decreases in overdose death rates were slightly higher among males than females, with
227 25.7% and 21.1% decreases, respectively. The largest percent decreases in overdose death rates
228 were seen among individuals aged 15-24 (35.7% decrease) and 25-34 years (31.9% decrease).
229 Older individuals generally had smaller decreases, and individuals age ≥75 experienced a small
230 increase (of 2.9%).
231
232 **Discussion**
233 The US is in the midst of a historic moment in the trajectory of the overdose crisis, as mortality
234 rates decreased steadily between mid-2023 through the end of 2024. Previous studies have
235 demonstrated that overdose deaths in the US could be described nearly perfectly with an
236 exponential growth curve.[6,13] Here we find that for the first time since the early 2000s, death
237 rates fell below this exponential growth pattern. Prior deviations from the exponential curve
238 have been documented, but these have generally included transient deviations above the curve,
239 followed by return to exponential growth.[13] Our findings suggest that the downward trends
240 observed in 2023-2024 represent the first sustained, high-magnitude departure below
241 exponential growth in the modern history of the US overdose crisis.
242
243 The permanence of this encouraging trend will depend on future shifts in the illicit drug market,
244 substance use behaviors, and policies. Despite progress, overdose death rates in the US remain

245 at about 400% of the magnitude seen at the turn of the century in the year 2000 and continue
246 to be far higher than those among other developed nations.[19] The nearly 80,000 lives lost to
247 overdose in 2024 remains a staggering quantity of preventable mortality.
248
249 Although the beginning of these downward trends was previously reported,[3] here we provide
250 newfound details documenting the continued trajectory, significance, and profundity of these
251 changes. We show that in 2024, for the first time, wave four of the crisis (defined by fentanyl in
252 combination with stimulants), is also decreasing in magnitude. We also highlight that not all
253 segments of the US overdose crisis are shrinking. Fatalities involving stimulants and xylazine
254 have grown and continue to represent important public health challenges. Importantly, other
255 novel substances, such as medetomidine, nitazenes, designer benzodiazepines, and carfentanil
256 have emerged in hotspots across the country.[10,20–23] Should one or more of these novel
257 synthetic substances proliferate widely and drive rising overdose risk, a return to exponential
258 growth could occur at a national level.
259
260 Our findings also suggest that stimulants and xylazine are each likely to continue to represent
261 growing challenges. We find that cocaine- and methamphetamine-involved deaths increased in
262 recent years and represent a growing share of all overdose fatalities. Other stimulant-related
263 health harms such as substance-induced psychosis, have also risen.[24] It is important to note that
264 the majority of stimulant-related burden of disease stems from slower epidemiological
265 processes compared to overdose, such as morbidity and accelerated mortality due to
266 cardiovascular, neurovascular, pulmonary, and psychiatric consequences.[25] As stimulants

267 continue to induce a growing share of addiction-related burden of disease, a focus on overdose
268 mortality as the defining indicator of the public health impact of substance use disorders may
269 be increasingly insufficient. Instead, more comprehensive measures such as disability adjusted
270 life years (DALYS)[25] that account for morbidity may more completely reflect the trajectory of the
271 US addiction crisis.
272
273 Recent decreases in overdoses have not occurred equally by geography, and some marked
274 reversals of prior trends were observed. After decades of being the least affected region,
275 overdose deaths are now the highest in the Western US. This may reflect the lagged course of
276 the overdose crisis in the West, with the region trailing behind the rest of the country in
277 decreases. Alternatively, it may reflect other unique dynamics in the Western region of the US,
278 including distinct illicit drug supply lines, a higher availability of illicitly manufactured fentanyl
279 (especially in pill form), and hotspots with increasing fentanyl use.[22,26,27]
280
281 After several years of rapidly widening inequalities in race/ethnicity, 2024 showed some small,
282 albeit encouraging, decreases in disparities in overdose mortality, with Black and African
283 Americans having the largest relative decrease between 2023 and 2024, falling by nearly one-
284 third in a single year. Nevertheless, the magnitude of inequalities remains quite large. In
285 particular, the mortality rate among American Indian and Alaska Natives remained double that
286 of the general population. Policies targeting community and system level factors associated with
287 inequitable health will be needed to address these persistent disparities.[12,28,29]
288

289 The decreases in overdose mortality in 2023-2024 in the US are likely multifactorial in nature,
290 reflecting several overlapping epidemiological and demographic phenomena.[3,30,31] Deaths have
291 now returned to pre-pandemic levels, as numerous social, economic, and epidemiological
292 consequences of the pandemic have also begun to recede.[14] The availability and use of the
293 opioid overdose antidote naloxone have been considerably scaled up in recent years, which is
294 likely playing an important role. Some evidence suggests that shifts in the illicit fentanyl supply
295 are also key to driving recent dynamics, with lower potency and variability of illicit opioids, and
296 the inclusion of high rates of fillers and adulterants leading to a lower overall opioid
297 potency.[30,32] The widespread shift from injecting to smoking opioids has also been associated
298 with decreased overdose rates.[33,34] There are also likely a reduced number of individuals that
299 are susceptible to overdose, given increased awareness of the risks of illicit fentanyl, and the
300 premature mortality of a large segment of previously susceptible individuals.[3,30] Further
301 research is needed to assess the relative contribution of each of these factors to the observed
302 decreases, and guide continued prevention.
303
304 Some of these observed trends may also simply reflect, at least in part, an overall 'regression to
305 the mean' as trends homogenize in the context of nearly universal decreases. Examining
306 demographic and geographic categories highlights that the states and demographic groups with
307 the highest mortality rates generally experienced the greatest decreases.
308 **Limitations**
309 Caution should be used in extrapolating from the gains achieved in 2024 to future decreases.
310 Due to inherent lags in overdose toxicology testing, the mortality records from 2024 are

provisional in nature and may change when final records are subsequently released.[35] However, in previous years, differences between provisional and final trends have been relatively small and have not changed the overall directionality of trends. Additionally, the race/ethnicity categorizations used here have limitations, especially for among American Indian and Alaska Native individuals, which may mask the magnitude of inequalities[36].

**Conclusions**

Recent decreases in overdose deaths are encouraging, relatively unprecedented, and represent the first major deviation below the exponential growth curve since the start of the US overdose crisis. However, policymakers, clinicians, and public health officials should be prepared for the possibility that a return to exponential growth could occur, especially if novel synthetic drugs once again dramatically change the risk environment of illicit drug use.

Despite recent progress, US overdose mortality remains a global outlier.[19] The country saw about 80,000 deaths in 2024. If the US population had the same overdose death rate as Western Europe, about 9,000 lives would have been lost.[25] Greater investments are needed to sustainably reverse the course of this large-magnitude, preventable mortality crisis, via evidence-based approaches such as medications for opioid use disorder, harm reduction, and access to addiction-related treatment.

Some encouraging, yet very early, improvements in racial/ethnic inequalities in overdose mortality have also been seen, after profoundly worsening during the COVID-19 pandemic.[12] Yet

disparities remain, even as the national trend in deaths now declines. More progress can be made with tailored solutions to reduce overdose deaths among the most affected groups.[12]

**Funding**

JRF received funding from the National Institute on Drug Abuse (DA049644) and the National Institute of Mental Health (MH101072). JP received support from the National Institute on Drug Abuse of the National Institutes of Health (R01DA057289 and U01DA051126). CLS was supported by National Institute on Drug Abuse (R01DA057630; K01DA05771**).** AB was supported by National Institute on Drug Abuse (R33DA061260 and DP2DA049295). Funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

**Conflicts of Interest**

JP reported receiving personal fees from the Washington-Baltimore High Intensity Drug Trafficking Areas program, Elsevier, Wiley, Rutgers University, Arizona State University, the University of Southern California, Queensland University, the National Network of Public Health Institutes, Alta Mira Recovery programs, and Dartmouth University, and nonfinancial support from NIH/NIDA, the University of Florida, Rx Summit, the American College of Neuropsychopharmacology, and the Reagan-Udall Foundation for the FDA during the conduct of the study. DC reports personal fees from Celero Systems, and Motley-Rice LLC outside the submitted work. All other authors declare no conflict of interest.




**Figure 1. Simplified Representation of the Four Waves of the US Overdose Crisis**
Based on the general approach from Friedman and Shover, the four waves of the US overdose crisis are shown in a simplified schema. Wave one is represented by prescription opioids (with fentanyl co-involvement deleted), wave 2 is shown by deaths involving heroin (without fentanyl). Wave 3 and 4 correspond to fentanyl-involved deaths without, and with, stimulants, respectively. Xylazine and stimulants without fentanyl are shown as examples of more recent drug trends that are not decreasing. Note that most xylazine-involved deaths also involve fentanyl. Data from 2024 are provisional and may slightly underestimate final numbers.

371




**Figure 2. Overdose Death Rates by Year and Substance Co-Involvement, 1980-2024**
A) National-level estimates of overdose deaths per 100,000 are shown by year from 1980 to 2024. Following the general approach established by Jalal et al., an exponential line of best fit is shown, estimated using data from 1980-2016 with a 95% uncertainty interval. The vertical dashed line shows the portion of the graph corresponding to part B, for which drug-specific data were available from 1999-2024. B) Drug overdose death rates per 100,000 are shown by specific substance involvement. Fentanyl-involved deaths are shown separately by stimulant co-involvement status. *Deaths for methamphetamine (meth), cocaine, commonly prescribed opioids (Rx Opioids) and heroin are shown removing deaths co-involved with fentanyl. Data from 2024 are provisional and may slightly underestimate final numbers.




**Figure 3. Monthly Overdose Mortality by Region, 2018-2024**
The death rate per 100,000 people is shown by month and US Census Region. Monthly data are annualized by multiplying by 12 to reflect the magnitude of annual mortality rates. Monthly data for the entire US are also shown in Black. Data from 2024 are provisional and may slightly underestimate final numbers.




**Figure 4. Overdose Deaths by Stimulant and Fentanyl Involvement**
The total number of annual overdose deaths each year is shown by categories of fentanyl and stimulant involvement. Data from 2024 are provisional and may slightly underestimate final numbers.




**Figure 5. Percent Change and Level of Overdose Deaths Between 2023-2024**
Top: percent change in overdose death rate is shown between 2023 and 2024 for several stratifying variables. A horizontal dashed line shows the national average decrease in overdose deaths for this period. Region and county refer to the geography of residence of each death, not occurrence location of the deceased. Data are shown from the 10 counties and 10 states with the highest total number of deaths in 2024. Bottom: the death rate per 100,000 in 2023 and 2024 is shown for the same stratifying variables. A horizontal dashed line shows the average overdose mortality rate in 2024. Data from 2024 are provisional and may slightly underestimate final numbers.




**Figure 6. State-Level Percent Change and Level in Overdose Deaths, 2024**
Top: the percent change in overdose deaths between 2023 and 2024 is shown for the continental US by state. State refers to the geography of residence of each death, not occurrence location of the deceased. States are classified according to quartiles of decreases in percent change, or increasing status, for a total of 5 categories. Bottom: the death rate per 100,000 population is shown by state for 2024, with quintiles shown by color. Data from 2024 are provisional and may slightly underestimate final numbers.

## References


1. *U.S. Overdose Deaths Decrease in 2023, First Time Since 2018*. Centers for Disease Control and Prevention; 2024. https://www.cdc.gov/nchs/pressroom/nchs_press_releases/2024/20240515.htm
2. Ahmad F, Cisewski J, Rossen L, Sutton P. *Provisional Drug Overdose Death Counts. National Center for Health Statistics. 2025.*; 2020. https://dx.doi.org/10.15620/cdc/20250305008
3. Post LA, Ciccarone D, Unick GJ, et al. Decline in US Drug Overdose Deaths by Region, Substance, and Demographics. *JAMA Netw Open*. 2025;8(6):e2514997. doi:10.1001/jamanetworkopen.2025.14997
4. Ciccarone D. The rise of illicit fentanyls, stimulants and the fourth wave of the opioid overdose crisis. *Current Opinion in Psychiatry*. 2021;34(4):344-350. doi:10.1097/YCO.0000000000000717
5. Friedman J, Shover CL. Charting the fourth wave: Geographic, temporal, race/ethnicity and demographic trends in polysubstance fentanyl overdose deaths in the United States, 2010–2021. *Addiction*. 2023;118(12):2477-2485. doi:10.1111/add.16318
6. Jalal H, Buchanich JM, Roberts MS, Balmert LC, Zhang K, Burke DS. Changing dynamics of the drug overdose epidemic in the United States from 1979 through 2016. *Science*. 2018;361(6408):eaau1184. doi:10.1126/science.aau1184
7. Friedman J, Kim D, Schneberk T, et al. Assessment of Racial/Ethnic and Income Disparities in the Prescription of Opioids and Other Controlled Medications in California. *JAMA Internal Medicine*. 2019;179(4):469-476. doi:10.1001/jamainternmed.2018.6721
8. Ciccarone D. The triple wave epidemic: Supply and demand drivers of the US opioid overdose crisis. *Int J Drug Policy*. 2019;71:183-188. doi:10.1016/j.drugpo.2019.01.010
9. Friedman JR. Assessing an ICD-10 Code Approach for Estimating Xylazine-Involved Overdose Deaths in the United States. *Drug and Alcohol Dependence*. Published online July 2025:112781. doi:10.1016/j.drugalcdep.2025.112781
10. Gupta Rahul, Holtgrave David R., Ashburn Michael A. Xylazine — Medical and Public Health Imperatives. *New England Journal of Medicine*. 2023;388(24):2209-2212. doi:10.1056/NEJMp2303120
11. Shover CL, Falasinnu TO, Dwyer CL, et al. Steep increases in fentanyl-related mortality west of the Mississippi River: Recent evidence from county and state surveillance. *Drug Alcohol Depend*. 2020;216:108314. doi:10.1016/j.drugalcdep.2020.108314
12. Friedman JR, Nguemeni Tiako MJ, Hansen H. Understanding and Addressing Widening Racial Inequalities in Drug Overdose. *AJP*. 2024;181(5):381-390. doi:10.1176/appi.ajp.20230917
13. Jalal H, Burke DS. Exponential growth of drug overdose poisoning and opportunities for intervention. *Addiction*. 2022;117(5):1200-1202. doi:10.1111/add.15841
14. Friedman J, Akre S. COVID-19 and the Drug Overdose Crisis: Uncovering the Deadliest Months in the United States, January–July 2020. *Am J Public Health*. Published online April 15, 2021:e1-e8. doi:10.2105/AJPH.2021.306256
15. CDC WONDER. https://wonder.cdc.gov/
16. Compton WM, Einstein EB, Jones CM. Exponential increases in drug overdose: Implications for epidemiology and research. *International Journal of Drug Policy*. 2022;104:103676. doi:10.1016/j.drugpo.2022.103676
17. Han B, Cotto J, Etz K, Einstein EB, Compton WM, Volkow ND. Methamphetamine Overdose Deaths in the US by Sex and Race and Ethnicity. *JAMA Psychiatry*. Published online January 20, 2021. doi:10.1001/jamapsychiatry.2020.4321
18. O'Donnell J, Tanz LJ, Gladden RM, Davis NL, Bitting J. Trends in and Characteristics of Drug Overdose Deaths Involving Illicitly Manufactured Fentanyls — United States, 2019–2020. *MMWR Morb Mortal Wkly Rep*. 2021;70(50):1740-1746. doi:10.15585/mmwr.mm7050e3
19. Gumas E. *U.S. Overdose Deaths Remain Higher Than in Other Countries — Trend-Tracking and Harm-Reduction Policies Could Help*. Commonwealth Fund; 2025. https://www.commonwealthfund.org/blog/2025/us-overdose-deaths-remain-higher-other-countries-trend-tracking-and-harm-reduction?check_logged_in=1
20. Palamar JJ, Krotulski AJ. Medetomidine Infiltrates the US Illicit Opioid Market. *JAMA*. 2024;332(17):1425. doi:10.1001/jama.2024.15992
21. Samarasekera U. "Even worse than fentanyls": nitazenes in the USA. *The Lancet*. 2024;404(10469):2250-2251. doi:10.1016/S0140-6736(24)02663-1

22. Friedman J, Ciccarone D. The public health risks of counterfeit pills. *The Lancet Public Health*. 2025;10(1):e58-e62. doi:10.1016/S2468-2667(24)00273-1
23. Ciccarone D. The Donovan Memorial Lecture: 'Fentanyl-Plus': A New Era of Fentanyl Polydrug Combinations in The North American Overdose Crisis. *Journal of Medical Toxicology*. 2025;In Press.
24. Calcaterra SL, Yamkovoy K, Swathi PA, et al. U.S. trends in methamphetamine-involved psychiatric hospitalizations in the United States, 2015-2019. *Drug Alcohol Depend*. 2024;262:111409. doi:10.1016/j.drugalcdep.2024.111409
25. Naghavi M, Ong KL, Aali A, et al. Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021. *The Lancet*. 2024;403(10440):2100-2132. doi:10.1016/S0140-6736(24)00367-2
26. Palamar JJ, Fitzgerald N, Carr TH, Cottler LB, Ciccarone D. National and regional trends in fentanyl seizures in the United States, 2017–2023. *International Journal of Drug Policy*. Published online May 13, 2024:104417. doi:10.1016/j.drugpo.2024.104417
27. Montero F, Bourgois P, Friedman J. Potency-Enhancing Synthetics in the Drug Overdose Epidemic: Xylazine ("Tranq"), Fentanyl, Methamphetamine, and the Displacement of Heroin in Philadelphia and Tijuana. *Journal of Illicit Economies and Development*. 2022;4(2):204-222. doi:10.31389/jied.122
28. Gondré-Lewis MC, Abijo T, Gondré-Lewis TA. The Opioid Epidemic: a Crisis Disproportionately Impacting Black Americans and Urban Communities. *J Racial and Ethnic Health Disparities*. 2023;10(4):2039-2053. doi:10.1007/s40615-022-01384-6
29. Bauer C, Hassan GH, Bayly R, et al. Trends in Fatal Opioid-Related Overdose in American Indian and Alaska Native Communities, 1999–2021. *American Journal of Preventive Medicine*. 2024;66(6):927-935. doi:10.1016/j.amepre.2024.01.019
30. Dowell D, Nataraj N, Rikard M, Park J, Zhang K, Baldwin G. Why have overdose deaths decreased? Widespread fentanyl saturation and decreased drug use among key drivers. *The Lancet Regional Health – Americas*. doi:10.1016/j.lana.2025.101226
31. *CDC Reports Nearly 24% Decline in U.S. Drug Overdose Deaths*.; 2025. https://www.cdc.gov/media/releases/2025/2025-cdc-reports-decline-in-us-drug-overdose-deaths.html
32. Shover CL, Koncsol AJ, Godvin ME, et al. High variation in purity of consumer-level illicit fentanyl samples in Los Angeles, September 2023–April 2025. *International Journal of Drug Policy*. 2025;145:104977. doi:10.1016/j.drugpo.2025.104977
33. Eger WH, Abramovitz D, Bazzi AR, et al. Changes in injecting versus smoking heroin, fentanyl, and methamphetamine among people who inject drugs in San Diego, California, 2020–2023. *Drug and Alcohol Dependence*. 2024;259:111318. doi:10.1016/j.drugalcdep.2024.111318
34. Karandinos G, Unick J, Ciccarone D. Mortality risk among individuals who smoke opioids compared with those who inject: A propensity score-matched cohort analysis of United States national treatment data. *Addiction*. 2025;120(5):1040-1045. doi:10.1111/add.16740
35. Spencer MR. Timeliness of Death Certificate Data for Mortality Surveillance and Provisional Estimates. *CDC Vital Statistics Rapid Release*. Published online 2016:8.
36. Anderson RN, Copeland G, Hayes JM. Linkages to Improve Mortality Data for American Indians and Alaska Natives: A New Model for Death Reporting? *Am J Public Health*. 2014;104(S3):S258-S262. doi:10.2105/AJPH.2013.301647